PLos One:阿来替尼与克唑替尼作为ALK+晚期非小细胞肺癌一线治疗的成本-疗效比较

2020-01-17 xiangting MedSci原创

使用阿来替尼对ALK+ NSCLC进行一线治疗的临床疗效优于克唑替尼,并且在法国范围内具有成本-疗效。

这项研究目的是评估在法国与克唑替尼相比,阿来替尼作为ALK+晚期非小细胞肺癌一线治疗的成本-疗效。

这项研究使用具有三个离散健康状态(无进展生存、进展后生存和死亡)的分区生存模型。生存概率来自一项比较阿来替尼与克唑替尼的III期随机临床试验(ALEX)。除了试验持续时间(18个月)之外,两种治疗的疗效被认为是相同的。出现不良事件或脑转移被认为是并发事件。应用了从EQ-5D获取的效用(以及并发不良事件的无效用)。费用是使用标准法国国家公共卫生费率分配的。

阿来替尼的预计平均总生存期为4.62年,克唑替尼为4.18年。阿来替尼的预期平均无进展生存期为30.30个月,克唑替尼为16.13个月。阿来替尼的预计质量调整寿命年为3.40,克唑替尼为2.84。该模型在整个生命周期内的总治疗费用预计为246,022欧元(阿来替尼)和195,486欧元(克唑替尼)。额外费用主要归因于获得治疗的费用和进展前的治疗花费。阿来替尼与脑转移和进展后治疗的相关成本较低相关。每获得1生命年的增量成本为115,334欧元/年,成本效益比的增量为90,232欧元/ QALY

使用阿来替尼对ALK+ NSCLC进行一线治疗的临床疗效优于克唑替尼,并且在法国范围内具有成本-疗效。

原始出处:

Marine Sivignon. Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France. PLos One. 16 January 2020.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779677, encodeId=f2651e79677ce, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2311, encryptionId=f47023119c, topicName=ALK+)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Tue Mar 31 21:05:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059863, encodeId=076d20598636d, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Jan 31 12:05:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790374, encodeId=5c931e903748e, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Jul 07 08:05:00 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413152, encodeId=a17d14131522d, content=<a href='/topic/show?id=be329e849f6' target=_blank style='color:#2F92EE;'>#阿来替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97849, encryptionId=be329e849f6, topicName=阿来替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55fa2946741, createdName=nymo, createdTime=Sun Jan 19 08:05:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032386, encodeId=5236103238619, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jan 17 20:05:00 CST 2020, time=2020-01-17, status=1, ipAttribution=)]
    2020-03-31 tcm99hq
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779677, encodeId=f2651e79677ce, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2311, encryptionId=f47023119c, topicName=ALK+)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Tue Mar 31 21:05:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059863, encodeId=076d20598636d, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Jan 31 12:05:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790374, encodeId=5c931e903748e, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Jul 07 08:05:00 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413152, encodeId=a17d14131522d, content=<a href='/topic/show?id=be329e849f6' target=_blank style='color:#2F92EE;'>#阿来替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97849, encryptionId=be329e849f6, topicName=阿来替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55fa2946741, createdName=nymo, createdTime=Sun Jan 19 08:05:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032386, encodeId=5236103238619, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jan 17 20:05:00 CST 2020, time=2020-01-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1779677, encodeId=f2651e79677ce, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2311, encryptionId=f47023119c, topicName=ALK+)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Tue Mar 31 21:05:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059863, encodeId=076d20598636d, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Jan 31 12:05:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790374, encodeId=5c931e903748e, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Jul 07 08:05:00 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413152, encodeId=a17d14131522d, content=<a href='/topic/show?id=be329e849f6' target=_blank style='color:#2F92EE;'>#阿来替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97849, encryptionId=be329e849f6, topicName=阿来替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55fa2946741, createdName=nymo, createdTime=Sun Jan 19 08:05:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032386, encodeId=5236103238619, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jan 17 20:05:00 CST 2020, time=2020-01-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1779677, encodeId=f2651e79677ce, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2311, encryptionId=f47023119c, topicName=ALK+)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Tue Mar 31 21:05:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059863, encodeId=076d20598636d, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Jan 31 12:05:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790374, encodeId=5c931e903748e, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Jul 07 08:05:00 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413152, encodeId=a17d14131522d, content=<a href='/topic/show?id=be329e849f6' target=_blank style='color:#2F92EE;'>#阿来替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97849, encryptionId=be329e849f6, topicName=阿来替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55fa2946741, createdName=nymo, createdTime=Sun Jan 19 08:05:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032386, encodeId=5236103238619, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jan 17 20:05:00 CST 2020, time=2020-01-17, status=1, ipAttribution=)]
    2020-01-19 nymo
  5. [GetPortalCommentsPageByObjectIdResponse(id=1779677, encodeId=f2651e79677ce, content=<a href='/topic/show?id=f47023119c' target=_blank style='color:#2F92EE;'>#ALK+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2311, encryptionId=f47023119c, topicName=ALK+)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Tue Mar 31 21:05:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059863, encodeId=076d20598636d, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Fri Jan 31 12:05:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790374, encodeId=5c931e903748e, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Jul 07 08:05:00 CST 2020, time=2020-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413152, encodeId=a17d14131522d, content=<a href='/topic/show?id=be329e849f6' target=_blank style='color:#2F92EE;'>#阿来替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97849, encryptionId=be329e849f6, topicName=阿来替尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55fa2946741, createdName=nymo, createdTime=Sun Jan 19 08:05:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032386, encodeId=5236103238619, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Fri Jan 17 20:05:00 CST 2020, time=2020-01-17, status=1, ipAttribution=)]
    2020-01-17 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

聚合物胶束紫杉醇在晚期非小细胞肺癌治疗中获突破,或将成为标准化疗方案

晚期非小细胞肺癌患者,或将迎来新的化疗标准方案。2019年9月7日至10日,2019世界肺癌大会(WCLC)在西班牙巴塞罗那召开。会上,广东省人民医院吴一龙教授口头报告了注射用聚合物胶束紫杉醇一线治疗非小细胞肺癌(NSCLC)的Ⅲ期研究结果。临床结果表明,无论疗效还是安全性,该新药研究均大幅优于同类产品,应作为晚期非小细胞肺癌(NSCLC)治疗的新化疗标准方案。上海谊众生物技术有限公司获悉,该

晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2019版)

目前已有3个抗血管生成药物在我国获批用于治疗晚期NSCLC患者,包括血管内皮生长因子(va scula rendothelial growth factor, VEGF)抑制剂贝伐珠单抗、重组人血管内皮抑制素[8]和小分子多靶点酪氨酸激酶抑制剂(tyrosine kinase inhibitor, TKI)安罗替尼。这三种药品均已进入国家医保目录。因此,随着我国抗血管生成药物的不断发展以及药物可及

泰瑞沙是**一个单药一线治疗让EGFR突变晚期非小细胞肺癌中位总生存期超过3年的药物

阿斯利康今日宣布了详细的三期临床试验FLAURA的总生存期(OS)数据,该试验用于评估泰瑞沙(甲磺酸奥希替尼片)一线用于治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的疗效。 临床数据显示该试验达到了次要研究终点,相比于之前针对此类患者的标准治疗方案吉非替尼或厄洛替尼,奥希替尼显示出总生存期既有统计学的显著改善,又有临床意义上的改善(HR 0.799 [95% C

酪氨酸激酶受体AXL抑制剂Bemcentinib联合Keytruda,用于晚期非小细胞肺癌的2期临床达到终点

Bergenbio宣布其试验药物酪氨酸激酶受体AXL抑制剂bemcentinib(BGB324)联合Keytruda(pembrolizumab),用于先前治疗过的晚期非小细胞肺癌(NSCLC)患者II期临床试验达到了主要终点,成功提高了总缓解率(ORR)。

Lancet Oncol:Nivolumab治疗与晚期非小细胞肺癌患者4年生存期

研究发现,与Docetaxel相比,晚期非小细胞肺癌患者接受Nivolumab治疗可获得更长的反应持续时间

百时美施贵宝公布CheckMate 227最终临床结果,数据喜人!

2019年9月28日,百时美施贵宝(纽约证券交易所代码:BMY)今日公布了III期临床研究CheckMate 227第一部分最终结果,这一研究评估了欧狄沃联合低剂量伊匹木单抗用于一线治疗晚期非小细胞肺癌(NSCLC)患者的疗效。欧狄沃联合低剂量伊匹木单抗达到了研究的独立共同主要终点,即PD-L1≥1%的患者中的总生存(OS)期。研究结果显示,与化疗相比,该联合治疗在PD-L1≥1%的患者中总生存获